Clinical bottom line
Chronic pruritic nummular eczema (CNE) remains a challenging dermatologic condition with limited approved systemic therapies. Emerging systemic treatments, including newer immunomodulators and biologics, show promise in reducing lesion severity and pruritus in refractory cases. However, robust, large-scale clinical trial data remain sparse, and current evidence is largely extrapolated from small cohorts or related eczematous disorders. Clinicians should consider these options cautiously, balancing potential benefits against safety profiles and individual patient factors.
What the evidence shows
Nummular eczema is a chronic inflammatory dermatosis characterized by well-demarcated, pruritic, coin-shaped plaques, often resistant to topical therapies (Bruckbauer et al., 2003). Traditional management focuses on emollients, topical corticosteroids, and avoidance of irritants, but systemic treatments are considered for severe or refractory disease (Todorova et al., 2015).
Recent literature highlights several systemic agents under investigation or off-label use for CNE:
- Systemic corticosteroids provide rapid symptom relief but are limited by adverse effects and relapse risk upon tapering (Bruckbauer et al., 2000). Their use is generally reserved for short courses.
- Immunosuppressants such as cyclosporine and methotrexate have demonstrated efficacy in small case series, improving lesion clearance and pruritus intensity (Todorova et al., 2023). However, evidence is limited by small sample sizes and lack of randomized controlled trials.
- Biologic therapies targeting key inflammatory pathways implicated in eczema pathogenesis, notably IL-4 and IL-13, are emerging as promising options. Dupilumab, an IL-4 receptor alpha antagonist approved for atopic dermatitis, has shown anecdotal benefit in nummular eczema patients with overlapping atopic features (Zemlok et al., 2024). Yet, dedicated trials in pure CNE populations are lacking.
- Janus kinase (JAK) inhibitors, which modulate multiple cytokine pathways, are under early investigation. Their broad immunomodulatory effects may address the complex inflammatory milieu of CNE, but clinical data remain preliminary.
Overall, the evidence base for systemic treatments in CNE is largely derived from extrapolation of atopic dermatitis and other eczematous conditions, highlighting a significant knowledge gap (Bruckbauer et al., 2003; Todorova et al., 2023).
Caveats and uncertainty
The heterogeneity of nummular eczema, often overlapping with atopic dermatitis or contact dermatitis, complicates patient selection and interpretation of treatment outcomes (Bruckbauer et al., 2003). Many studies lack rigorous diagnostic criteria or exclude comorbid dermatoses, limiting generalizability.
Most systemic treatment data come from small observational studies or case reports without control arms, increasing susceptibility to bias and placebo effects. Long-term safety data for newer agents in CNE are absent, and extrapolation from atopic dermatitis populations may not fully capture distinct disease biology or treatment responses (Zemlok et al., 2024).
Furthermore, the chronic relapsing nature of CNE necessitates sustained treatment strategies, yet optimal duration and maintenance regimens for systemic therapies remain undefined (Todorova et al., 2023).
How this may change practice
For patients with severe, refractory nummular eczema unresponsive to optimized topical regimens, systemic immunomodulators such as cyclosporine or methotrexate may be considered, acknowledging limited high-quality evidence and potential toxicities.
Biologic therapies approved for atopic dermatitis, particularly dupilumab, represent a promising off-label option for select patients exhibiting overlapping atopic features, pending further validation. Clinicians should monitor emerging data on JAK inhibitors and other novel agents as potential future options.
Shared decision-making is essential, emphasizing the experimental nature of systemic treatments in CNE, close monitoring for adverse effects, and individualized risk-benefit assessment. Multidisciplinary collaboration and referral to specialized dermatology centers may facilitate access to emerging therapies and clinical trials.